Titanate Nanotubes Engineered with Gold Nanoparticles and Docetaxel to Enhance Radiotherapy on Xenografted Prostate Tumors.

Fiche publication


Date publication

décembre 2019

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOIDOT Romain, Dr MIRJOLET Céline, Pr MILLOT Nadine, Pr ROUX Stéphane, Dr BOUDON Julien


Tous les auteurs :
Loiseau A, Boudon J, Oudot A, Moreau M, Boidot R, Chassagnon R, Saïd NM, Roux S, Mirjolet C, Millot N

Résumé

Nanohybrids based on titanate nanotubes (TiONts) were developed to fight prostate cancer by intratumoral (IT) injection, and particular attention was paid to their step-by-step synthesis. TiONts were synthesized by a hydrothermal process. To develop the customengineered nanohybrids, the surface of TiONts was coated beforehand with a siloxane (APTES), and coupled with both dithiolated diethylenetriaminepentaacetic acidmodified gold nanoparticles (Au@DTDTPA NPs) and a heterobifunctional polymer (PEG) to significantly improve suspension stability and biocompatibility of TiONts for targeted biomedical applications. The prefunctionalized surface of this scaffold had reactive sites to graft therapeutic agents, such as docetaxel (DTX). This novel combination, aimed at retaining the AuNPs inside the tumor via TiONts, was able to enhance the radiation effect. Nanohybrids have been extensively characterized and were detectable by SPECT/CT imaging through grafted Au@DTDTPA NPs, radiolabeled with In. In vitro results showed that TiONtsAuNPsPEGDTX had a substantial cytotoxic activity on human PC3 prostate adenocarcinoma cells, unlike initial nanohybrids without DTX (Au@DTDTPA NPs and TiONtsAuNPsPEG). Biodistribution studies demonstrated that these novel nanocarriers, consisting of AuNP- and DTXgrafted TiONts, were retained within the tumor for at least 20 days on mice PC3 xenografted tumors after IT injection, delaying tumor growth upon irradiation.

Mots clés

biodistribution, colloidal stability, cytotoxicity, docetaxel, gold nanoparticles, nanocarrier, prostate cancer, radiotherapy, titanate nanotubes, vectorization

Référence

Cancers (Basel). 2019 Dec 6;11(12):